echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > JCEM: Relationship between metformin and COVID-19 susceptivity in patients with type 2 diabetes

    JCEM: Relationship between metformin and COVID-19 susceptivity in patients with type 2 diabetes

    • Last Update: 2021-02-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Diabetes has become an important risk factor for death in PATIENTs with COVID-19.
    metformin is the most commonly used anti-sugar drug and has been speculated to affect susceptibility and outcomes in PATIENTs with COVID-19 through a variety of mechanisms.
    recently, a research paper was published in Journal of Clinical Endocrinology and Metabolism, an authoritative journal in the field of endocrine and metabolic diseases, to investigate whether metformin use in diabetics was associated with COVID-19 susceptivity and its outcomes.
    researchers used a large UK primary care data set to conduct a trend-matching queue study and compared adult patients with type 2 diabetes who currently use metformin and other sugar-lowering drugs (MF-plus) with adult patients currently treated with a sugar-lowering drug (MF-) that does not include metformin.
    results were confirmed COVID-19, suspected/confirmed COVID-19 and related mortality.
    also conducted a negative controlled outcome (back pain) analysis.
    29,558 patients in the MF plus group and 10,271 patients in the MF-group met the inclusion criteria.
    in the trend score matching analysis, the adjusted risk ratios for suspected/confirmed COVID-19, confirmed COVID-19 and COVID-19-related mortality were 0.85 (95% CI 0.67, respectively. 1.08), 0.80 (95% CI is 0.49, 1.30) and 0.87 (95% CI is 0.34, 2.20).
    factors were not observed in the negative outcome control analysis.
    metformin is not associated with COVID-19 risk or COVID-19-related deaths.
    , it is safe to continue to use metformin to improve blood sugar control in diabetic patients.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.